Kornimate/medical-research-clean huggingface dataset:
a study in dentinal hypersensitivity (dh) participants to assess the efficacy of an occluding dentifrice.

Conditions: Dentin Sensitivity

Summary: this study will investigate the longitudinal efficacy of two experimental oral rinses, one containing 1.5% weight/weight (w/w) dipotassium oxalate monohydride (kox) /0 parts per million (ppm fluoride) and the other 2.0% w/w kox /45ppm fluoride, for the relief of dentinal hypersensitivity (dh), compared to a placebo oral rinse, when used as an adjunct to twice daily brushing with a standard fluoride toothpaste.


Eligibility criteria:
inclusion criteria: * participants in good general health with no clinically significant/ relevant abnormalities in medical history or upon oral examination * pre-existing self reported and clinically diagnosed tooth sensitivity * at screening a minimum of 20 natural teeth and at least two accessible, non-adjacent teeth (incisors, canines or pre-molars) preferably in different quadrants with a signs of facial/cervical gingival recession and/or signs of erosion or abrasion (ear),tooth with modified gingival index (mgi) score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of ≤1 and tooth with signs of sensitivity measured by qualifying evaporative air assessment (y/n response). * at baseline, a minimum of 2 non-adjacent accessible teeth (incisors, canines or premolars) with dh (qualifying tactile threshold yeaple ≤ 20g, schiff sensitivity score ≥ 2) exclusion criteria: * participants with a known or suspected intolerance or hypersensitivity to study products * presence of chronic debilitating disease which could affect study outcomes * any condition which is causing dry mouth * use of an oral care product indicated for the relief of dentine hypersensitivity * participation in a dh treatment study in the 8 weeks prior to screening * taking daily doses of a medication/ treatment which could interfere with perception of pain or is causing dry mouth * require antibiotic prophylaxis for dental procedures * dental prophylaxis within 4 weeks of screening * treatment of periodontal disease within 12 months of screening * scaling or root planning within 3 months of screening * tooth bleaching within 8 weeks of screening * active caries or periodontitis * partial dentures, orthodontic appliances or dental implants which could affect study outcomes * pregnant and breast-feeding females * main exclusions for test teeth: evidence of current or recent caries; treatment of decay within 12 months of screening; teeth with exposed dentine but with deep, defective or facial restorations; teeth used as abutments for fixed or removable partial dentures; teeth with full crowns or veneers, orthodontic bands or cracked enamel; sensitive teeth with contributing aetiologies other than erosion, abrasion or recession
whole breast irradiation with intensity modulated radiotherapy and simultaneously integrated boost for early stage breast cancer patients

Conditions: Breast Cancer

Summary: this is a phase ii study. in patients with node-negative invasive breast cancer or carcinoma in situ treated by breast conserving surgery, postoperative whole breast irradiation with inversely intensity modulated radiotherapy and a simultaneous integrated boost is technically feasible. the aim of this study is to evaluate the radiation toxicity, cosmetic outcome and local control rate in a single center


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group performance score﹤2 * all patients aged \>18 years and \< 70 years after breast conserving surgery. * on histological examination, the tumor must be dcis or invasive adenocarcinoma of the breast. * negative nodal status determined by sentinel node biopsy, or axillary dissection. axillary staging is not required for patients with dcis * no evidence of distant metastasis * gross disease may be unifocal or multifocal with pathologic (invasive and/or dcis) tumor size excised with negative margins（\>2mm） * surgical treatment of the breast must have been lumpectomy. re-excision of surgical margins is permitted. * the patient must consent to be in the study and must have signed an approved consent form. exclusion criteria: * eastern cooperative oncology group performance score≧2 * presence of extensive intraductal component (ductal carcinoma in situ occupying \> 25% of the primary invasive tumour and present adjacent to the primary tumour).suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign. * proven multicentric carcinoma (invasive cancer or dcis) in more than one quadrant of separated. * metastatic disease (m1) * pregnancy or lactating * surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. * psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol. * collagen vascular disease, specifically dermatomyositis with a cpk level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma. * prior breast or thoracic rt for any condition. * previous or concomitant malignancies except non-melanoma skin cancer, carcinoma in situ of the cervix, and invasive carcinoma of the colon, thyroid, cervix, or endometrium treated five years prior to study entry. * synchronous chemotherapy or target therapy is not permitted. * refusal of the patients to be included in the study

Keywords: breast cancer radiotherapy simultaneous integrated boost tumor bed imrt
efficacy of the cmi magnetocardiograph in diagnosing acute coronary syndromes in patients presenting with high risk unstable angina.

Conditions: Myocardial Ischemia

Summary: a magnetocardiograph (mcg) is a device capable of recording of magnetic fields arising from the electrical activity of the heart with traces similar to an electrocardiogram (ecg). this system was developed as a noninvasive, non-contact diagnostics of obstructive coronary artery disease (cad), and especially of lack of oxygen in the heart as in a heart attack. the overall objective of this study is to demonstrate the efficacy of this mcg device for the detection and diagnosis of lack of oxygen of the heart in patients with chest pain.

coronary artery disease is the leading cause of death in the united states. the non invasive detection of acute coronary syndromes (acs's) remains a clinical challenge. electrocardiogram (ecg) may only diagnose myocardial infarction in 50 % of the cases. magnetocardiography is a new and noninvasive method capable of measuring and mapping the magnetic field that is generated during the cardiac cycle. the electric current is affected by ischemic damage, which in turn alters the magnetic field. the magnetic field is not affected by body tissues, unlike the surface current measurements in ecg. comparisons: the diagnostic accuracy of the cmi-magnetocardiograph will be compared to that of the ecg in diagnosing high risk unstable angina.

Eligibility criteria:
inclusion criteria: * patients classified as having high risk unstable angina according to the acciaha guidelines. * age ≥ 18 years. exclusion criteria: * hemodynamically unstable patients. * patients who just prior to or just after admission exhibit tachycardia with heart rates exceeding 150 bpm. * patients with third degree av block. * patients with pacemakers or internal cardiac defibrillators. * patients who cannot lie in a supine position for the mcg examination. * patients who refuse entry into the registry
evaluation of a new invitation procedure to the french organized colorectal cancer screening program

Conditions: Colorectal Cancer

Summary: this is a randomized controlled trial comparing the effect on participation rates to colorectal cancer screening between an intervention arm (invitation letter to the screening program including a fit test with or without prior notification) and a control arm with the standard of care (invitation letter to visit the gp who will deliver the fit test).

the participation to the national screening program for colorectal cancer in france is low. in order to improve the performances of its organized program, the national cancer institute is planning to modify the invitation procedure. this is a pilot project and if an improvement in the program performances is reported, the invitation procedure may be scaled up. eligible individuals for colorectal cancer screening will be identified by the regional cancer screening coordinating centre and randomized into the intervention or control arms. they will be followed for fit test submission to the central laboratory (participation to screening). those who did not send their test will receive reminder letters. those who had a positive fit test will be followed up for coloscopy referral, and result of the coloscopy. comparison of the participation rates to screening program and to coloscopy among those with a positive fit test will be compared between the two study arms.

Eligibility criteria:
inclusion criteria: * women and men aged 50 to 74 years old * living in the study area (departments of ardennes, meurthe-et-moselle, and moselle, france) * at moderate risk of colorectal cancer, i.e. eligible to the organised programme and receiving the first invitation of the screening round (not a reminder letter) exclusion criteria: * outside the target age (less than 50 years old, or 75 years and more) * receiving the reminder letter * at high or very high risk of colorectal cancer

Keywords: colorectal cancer screening program pilot project randomised control trial france
sirolimus treatment in hospitalized patients with covid-19 pneumonia

Conditions: COVID-19

Summary: the main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with covid-19. the investigators will employ a randomized, double blind, placebo-controlled study design. 28 subjects were randomized in a 2:1 fashion to receive sirolimus or placebo. sirolimus will be given as a 6mg oral loading dose on day 1 followed by 2mg daily for a maximum treatment duration of 14 days or until hospital discharge, whichever happens sooner. chart reviews will be conducted daily to determine changes in clinical status, concomitant medications and laboratory parameters. study specific biomarkers will be measured at baseline and then at days 3, 7 and 14.


Eligibility criteria:
inclusion criteria: subjects enrolled in the trial must meet all of the following criteria. * confirmed covid-19 pneumonia * hypoxia as defined by room air oxygen saturation less than 92% or supplemental oxygen requirement * presence of at least one additional biomarker that has been shown to predict poor prognosis: a) serum ferritin ≥500ug/l, b) ldh ≥250u/l, c) d-dimer ≥1ug/l, or d) lymphopenia as defined by absolute lymphocyte count \<1,000/ul * age ≥ 18 years * completed informed consent exclusion criteria: subjects who meet any of the following criteria are not eligible for enrollment as study participants: * known allergy or hypersensitivity to sirolimus * inability or refusal to provide informed consent * advanced respiratory support (high flow oxygen ≥ 15 l/min, cpap, non-invasive or invasive mechanical ventilation) * active enrollment in other interventional clinical drug trials. co-enrollment in observational studies and biorepositories is allowed. * pregnant women * breast feeding * on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. a list of these medications is provided in section 12.3.4 * any clinically significant medical disease which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to): * history of liver cirrhosis * end stage renal disease or need for renal replacement therapy * decompensated heart failure * known active tuberculosis or history of incompletely treated tuberculosis * uncontrolled systemic bacterial or fungal infections * active viral infection other than covid-19
dipole density mapping of right and left atrial supraventricular tachycardia

Conditions: Supraventricular Tachycardia

Summary: use of dipole density mapping to identify activation in complex supraventricular tachycardias


Eligibility criteria:
inclusion criteria: 1. aged 18 to 75 years 2. scheduled for ablation of atypical atrial flutter or paroxysmal atrial fibrillation 3. able and willing to give informed consent exclusion criteria: 1. implanted prosthetic, artificial, or repaired cardiac valves in the chamber being mapped, permanent pacemaker or icd leads in the chamber being mapped, and/or hypercoagulopathy or an inability to tolerate anticoagulation . 2. myocardial infarction within the prior two months 3. cardiac surgery within the prior three months 4. intracardiac thrombus 5. clinically significant tricuspid valve regurgitation or stenosis 6. any cerebral ischemic event in the prior six months 7. pregnant or nursing 8. currently enrolled in any other clinical investigation
identification of the cutaneous microbiota in patients with cutaneous infection (microbiota)

Conditions: Skin Infections

Summary: identify the cutaneous microbiota on a cutaneous lesion (cellulite, wound, rash, etc.) on a swab, biopsies or abscess puncture and on "healthy" skin on a skin swab performed for cutaneous mapping to search for staphylococcal deposits.

cellulite is characterized by inflammation and an alleged infection of the skin and subcutaneous tissues. previous studies have shown a low yield of samples such as biopsy and needle aspiration of the order of 16%. the most common pathogens are staphylococcus aureus and streptococcus pyogenes. conventional cultivation has limitations such as the lack of detection of fastidious microorganisms, or the use of antibiotics. molecular diagnostic methods, such as detection of 16s ribosomal dna followed by amplification and pyrosequencing, have been used to overcome the limitations of microbial culture. in a recent study, the authors investigated the causes of acute cellulitis without performing drainage but skin biopsies from the infected site and another non-infected site by quantitative pcr, pyrosequencing, and conventional culture. pcr identified methicillin-resistant s. aureus methicillin in approximately 30% -40% of cases with similar frequency in infected and uninfected sites. in another study r. felis was found in not only bedsores, but also, swabs taken from healthy skin, as well as streptococcus pneumoniae, s. aureus and streptococcus group a. being engaged in the exploration of the human microbiota especially by culture we propose to extend the knowledge of this skin microbiota in patients hospitalized in infectious disease services.

Eligibility criteria:
inclusion criteria: * patient with skin infections at admission * patient requiring skin mapping * person informed of the study and having expressed no opposition to participate in the study. * affiliate or beneficiary of a social security exclusion criteria: * subject not agreeing to participate * vulnerable person: pregnant, parturient or nursing woman, person under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision.
effect of diabetes control on outcome in hospitalized patients: a national israeli study

Conditions: Diabetes

Summary: to test whether tight glucose control is associated with better clinical outcome compared to less-tight control, among diabetic patients hospitalized in internal medicine wards.

patient characteristics: patients admitted to internal medicine departments in public hospitals of israel who have pre-admission diagnosis of diabetes, or have a random plasma glucose \>200 mg/dl on admission eligibility criteria 1. age: \>18 years 2. fasting plasma glucose \> 140 mg/dl or non-fasting plasma glucose \>200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes 3. able to understand the study objective and methods and willing to provide a written informed consent 4. no significant liver disease 5. serum creatinine \<2.0 mg/dl exclusion criteria 1. significant cognitive impairment 2. history of hypoglycemia unawareness or clinical autonomic diabetic neuropathy 3. known allergy to insulin analogues 4. diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission process of patient recruitment and randomization: 1. enrolment of eligible patients signing the informed consent. 2. assignment of patients to different treatment arms according to randomization scheme provided by the central organizing committee. 3. the ratio of patients' assignment to the active or to the control study arm will be 1:1 for each participating ward. protocol: basal bolus insulin treatment will be applied to achieve tight glucose target (mean fasting blood glucose\<130 mg/dl and not above 180 mg/dl during the day) compared to patients treated to achieve less tight glucose targets (mean fasting blood glucose\<200 mg/dl and not above 220 mg/dl during the day)will influence cardiovascular and general clinical outcome. primary outcome: all-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital secondary outcomes: total number of in-hospital days during one year follow-up (including the index hospital admission) the rate of any major clinical events (all-cause mortality, hospital acquired infection, organ failure, need of ventilation support, need of vasoactive amine administration, need of central line insertion, hospital admission for stroke, acute coronary event, severe bacterial or fungal infection) during one year follow-up hypoglycemic events during index hospital stay.

Eligibility criteria:
inclusion criteria: 1. age: \>18 years 2. fasting plasma glucose \> 140 mg/dl or non-fasting plasma glucose \>200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes 3. able to understand the study objective and methods and willing to provide a written informed consent 4. no significant liver disease 5. serum creatinine \<2.0 mg/dl - exclusion criteria: 1. significant cognitive impairment 2. history of hypoglycemia unawareness or clinical autonomic diabetic neuropathy 3. known allergy to insulin analogues 4. diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission -

Keywords: cardio vascular outcome
peng and lfcn block versus lumbar plexus block for postoperative analgesia after total hip arthroplasty

Conditions: Post Operative Pain; Regional Block

Summary: regional anesthesia for postoperative analgesia in tha includes epidural anesthesia and peripheral nerve blocks. however epidural anesthesia has a great role in tha, it has become restricted as perioperative antithrombotic drugs are generally used for orthopedic patients. the study aim to evaluate and compare efficacy and safety of pericapsular nerve group block (peng) block and lateral femoral cutaneous nerve versus lumbar plexus block on postoperative analgesia in hip surgery.


Eligibility criteria:
inclusion criteria: (asa) physical status i to iii scheduled for hip surgery aged (30-70) years exclusion criteria: * drug allergy, * morbid obesity (bmi \>40 kg/m2), * coagulopathy, * psychiatric disorder, * opioid dependence, * patient refusal to give informed consent.

Keywords: peng lumber plexus hip surgery
neural mechanisms for appetitive responses to high reward foods

Conditions: Appetitive Behavior; Obesity

Summary: this study is aimed at understanding neuroendocrine responses to different types of sugars and how this influences feeding behavior among lean, overweight, and obese individuals.

the investigators have previously combined functional magnetic resonance imaging (fmri) with hormonal and behavioral assessments to better understand the impacts of glucose and fructose on appetite and its central regulation in humans and have made important observations in lean individuals linking fructose consumption to overeating and obesity. the investigators now propose to expand this work by examining the impacts of glucose and fructose ingested together (sucrose), as occurs in real life, and by examining effects of a common non-nutritive sweetener, sucralose, on brain and appetitive response. the investigators propose a random-order crossover design to determine the effects of caloric and non-nutritive sweeteners among lean, overweight, and obese participants. the investigators will measure circulating levels of hormones involved in satiety signaling, quantify food intake, and measure brain activity using blood-oxygen level dependent and arterial spin labeling methods and functional connectivity analyses.

Eligibility criteria:
inclusion criteria: * age 18-35 years, right-handed, weight change \<2% for at least 3 months prior to participation, no history of diabetes or other significant medical problems, fasting glucose \<126 mg/dl. * lean group: bmi of 19-24.9 kg/m2 * obese group: bmi 30-40 kg/m2 * overweight group: bmi of 25-29.9 kg/m2 exclusion criteria: * neurological, psychiatric or addiction disorder, fasting glucose ≥126 mg/dl, use of prescription medication (with the exception of contraceptives), tobacco use, contraindications to mri scanning (detailed in protection of human subjects), fructose intolerance, history of eating disorder, actively trying to lose weight.

Keywords: functional magnetic resonance imaging eating behavior sugar
the efficacy of a remote cognitive remediation therapy (crt) program on parkinson's disease

Conditions: Parkinson Disease

Summary: purpose/goal: to determine if a remote computerized cognitive remediation program (crt) can stabilize or improve cognitive functioning in a group of patients from the new york institute of technology academic health care center with parkinson's disease (pd) after three months of intervention. hypothesis: patients with pd who present with current cognitive deficits will show improvement in such deficits after three months of participation in a remotely supervised structured cognitive remediation therapy program (crt) compared to control subjects with pd who receive treatment as usual. research design: pilot study. prospective randomized treatment and control comparison pre-post study.


Eligibility criteria:
inclusion criteria: 1. subjects must be currently enrolled in the rock steady boxing program at the adele smithers parkinson's disease center. 2. subjects must be between 40 and 85 years old (including both ages) at the time of study screening. 3. subjects must have a diagnosis of parkinson's disease by a physician. 4. subjects must have a moca score of 20 or above. 5. subjects must demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in this research study. 6. subjects must have been clinically stable for 2 weeks prior to consent; in the judgment of the investigator. 7. subjects must have the visual, auditory, and motor capacity to use the intervention in the judgment of the principal investigator. 8. subjects must be technologically capable of utilizing a computer and navigating through the programs. 9. subjects must be mechanically capable of utilizing a computer and computer mouse. exclusion criteria: 1. subjects should not be participating in a concurrent research study or other interventional clinical trial 30 days prior to consenting. 2. subjects should not have a history of mental retardation or pervasive developmental disorder; or other co-morbid neurological disorder (e.g., epilepsy.) 3. subject is unable to physically use a computer or a computer mouse. 4. subject is unable to or refuses to give consent.